bioAffinity Technologies Sets Pricing for $1.75M Direct Offering, Private Placement, and Warrant Inducement
bioAffinity Technologies today announced agreements with three accredited investors to exercise outstanding warrants, totaling 1,041,667 shares of common stock, for gross proceeds of approximately $1,302,083. In exchange, the investors will…
Amylyx’s AMX0035 Gets Orphan Drug Status for Wolfram Syndrome in Europe
Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for AMX0035, its proprietary combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO) for treating Wolfram syndrome. This designation follows…
OS Therapies: Osteosarcoma Patient Advocacy and Advisory Board
OS Therapies Announces Formation of Osteosarcoma Patient Advocacy Advisory Board OS Therapies, a biopharmaceutical company specializing in cancer immunotherapy and Antibody Drug Conjugates (ADCs), has announced the establishment of a…
Coya Therapeutics to Present Alzheimer’s Study Results at CTAD24 in Madrid
Coya Therapeutics, a clinical-stage biotechnology firm specializing in biologics to enhance regulatory T cell (Treg) function, will present data from its phase 2, double-blind, placebo-controlled study of interleukin-2 (IL-2) for…
Agilent Gains FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for New TCR T-Cell Therapy
Agilent has announced that it has received FDA approval for the MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for…
Puma Biotechnology Announces Financial Results for Q2
Puma Biotechnology, a biopharmaceutical company, has released its financial results for the second quarter ending June 30, 2024. Comparisons are made between Q2 2024 and Q2 2023, unless specified otherwise.…
Neurocrine Biosciences Reports Q2 2024 Financial Results and Increases 2024 INGREZZA Sales Forecast
Neurocrine Biosciences today announced its financial results for the second quarter ending June 30, 2024, and provided an update on its 2024 financial outlook. Dr. Kevin Gorman, Chief Executive Officer…
Labcorp Reports Q2 2024 Financial Results
Labcorp reported strong revenue and EPS growth for the second quarter of 2024, reflecting significant momentum as the company progresses into the latter half of the year. Chairman and CEO…
CVS Health® Launches Unique Initiative to Aid Vulnerable Patients in Extreme Weather
Today, a groundbreaking environmental health impact initiative was announced to assist those most vulnerable to extreme weather events, which can exacerbate existing chronic conditions. Initially, the initiative will focus on…
Vertex Announces Financial Results for Q2 2024
Vertex Announces Q2 2024 Financial Results, Raises Full-Year Product Revenue Guidance Vertex today reported consolidated financial results for the second quarter ending June 30, 2024, and increased its full-year product…
AbbVie Finalizes Acquisition of Cerevel Therapeutics
AbbVie today announced the completion of its acquisition of Cerevel Therapeutics (NASDAQ: CERE), making Cerevel a part of AbbVie. “AbbVie’s acquisition of Cerevel strengthens our foundation in neuroscience and positions…
Lilly’s Tirzepatide Shows Success in Phase 3 Study for Heart Failure and Obesity
Lilly announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults…